The Staphylococcus aureus bacteraemia Network Adaptive Platform Trial is an innovative trial to evaluate a range of interventions with the aim of improving outcomes for patients with Staphylococcus aureus bacteraemia (AKA bloodstream infections).
This trial will include both adults and children.
The study includes sites from throughout Australia, New Zealand, Singapore, Canada, Israel and the UK and has the potential to include sites elsewhere in the world.
Subscribe to receive email updates about SNAP and the study results.
Professor Joshua S Davis PhD, FRACP, MBBS (Hons), DTM&H, Grad Cert Pop Health. Infectious Diseases Physician and NHMRC Career Development Fellow at the University of Newcastle and the Menzies School of Health Research.
Professor Steven YC Tong PhD, FRACP, MBBS (Hons), Grad Dip Epidemiol Biostats, Infectious Diseases Physician with the Victorian Infectious Diseases Service.
The SNAP trial includes all age groups because people of all ages.
A summary of how Staphylococcus aureus and penicillin have been instrumental in both the success and failure of one another since they met. Carly Botheras (PhD Candidate, Geelong Centre for Emerging Infectious Diseases, Barwon Health)
Amy Legg (Clinical Pharmacist) and Prof Marc Scheetz (Professor of Pharmacy and Pharmacology at Midwestern University) explain one of the proposed SNAP substudies involving novel urinary biomarkers.
